Summary COPD is a common and under-diagnosed disease which is increasing in prevalence worldwide. A more aggressive and optimistic approach must be adopted towards its management in primary care. This IPCRG Guideline on the management of COPD in primary care is fully consistent with GOLD guidelines. It highlights the goals of COPD treatment and the need for spirometric testing to make the diagnosis. It covers the classification of the disease according to disease severity, non-pharmacologic therapy including smoking cessation, avoidance of risk factors, patient education, pharmacologic therapy including the use of oxygen treatment, the management of exacerbations, the role of pulmonary rehabilitation, and the need for monitoring and ongoing care for COPD patients.
most countries, specific primary care guidelines are not available. Since clinical management which follows evidence-based guidelines yields better results for patients, it is important to have access to primary care guidelines which are specifically relevant to, and provided by, primary care. The International Primary Care Respiratory Group (IPCRG) asked primary care experts from several countries to develop primary care guidelines for the diagnosis and treatment of asthma, chronic obstructive pulmonary disease (COPD) and rhinitis. A brief summary of the expert report (which took three years to complete) was published as a handbook [1] 
in 2005.
This paper is devoted to the management of COPD and is specifically written for primary care health professionals. It is consistent with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines [2] , which we recommend should be consulted if a more detailed perspective is required. In addition to this section on COPD, the IPCRG guidelines consist of papers on the diagnosis of chronic respiratory diseases in primary care [3] , and the management of asthma [4] and rhinitis [5] . For the specific purpose of ranking the evidence in each of these publications, we have used the so-called Three Star System of the Royal College of General Practitioners [6] in order to score the evidence of the statements made (see box).
Introduction
COPD is a common and under-diagnosed disease which is increasing in prevalence worldwide. The disease causes persistent and progressive symptoms which can have major effects on the quality of life of the sufferer, and constitutes a heavy health and economic burden on nation states.
Sadly, despite the prevalence and seriousness of COPD, there is a widely-held view that little can be done to treat the disease other than to stop patients from smoking. This negative attitude, linked to a lack of understanding about modern management, is a major hurdle to providing patients with the symptomatic relief and help that they need. A much more aggressive and optimistic approach must be adopted, since there is clear evidence that the various treatments available improve patients in a variety of ways, albeit that they are unable to cure the disease. Breathlessness can be lessened, exercise levels and quality of life improved, and the frequency of acute exacerbations decreased. However, stopping smoking is the only action that will slow the rate of disease progression.
The most important primary care objective should be to improve quality of life. Every effort should be made to reduce exacerbations since a high frequency of exacerbations has been associated with a poorer quality of life and more rapid decline in lung function.
Treatment goals
While disease prevention is the ultimate goal, once COPD has been diagnosed, effective management should be aimed at the following goals:
• Prevent disease progression • Relieve symptoms • Improve exercise tolerance • Improve health status
• Prevent and treat complications • Prevent and treat exacerbations • Reduce mortality.
The aim should be to reach these goals with minimal side effects from treatment and at an affordable cost. 
Non-pharmacologic therapy
Non-pharmacologic therapy is extremely important in COPD because it includes the only treatment --smoking cessation --that can prevent the development and progression of the disease. Patient education and exercise training are also important, as is pulmonary rehabilitation, which can significantly improve health-related quality of life in many patients.
Smoking cessation
Stopping smoking is the only intervention that will slow the rate of progression of COPD and prolong life expectancy [7] *** . It will reduce the rate of decline in lung function to that of a nonsmoker in most patients who stop smoking. Smoking cessation is also the single most effective action to reduce the risk of developing COPD [8] [9] [10] . Details of evidence-based smoking cessation methods are provided in Appendix A. The need for reduction of exposure to passive or secondhand smoke should also be emphasised to COPD patients.
Avoidance of other risk factors
Occupational exposure Emphasise primary prevention, which is best achieved by elimination or reduction of exposure to the various occupational dusts and chemicals that can cause COPD ** . Occupations posing the greatest risk for COPD are linked to exposure to particulate matter such as coalmining. Coal dust alone in sufficient doses can produce airflow limitation. Secondary prevention, achieved through surveillance and early detection, is also important.
Indoor and outdoor air pollution
Encourage measures to reduce or avoid indoor air pollution from biomass fuel, which is often used in developing countries for cooking and heating. Improving ventilation in homes, using stoves that are more efficient and clean than biofuels, and substituting cleaner fuel, are the most practical solutions to this problem [11] .
Advise patients who live in larger cities or areas of significant outdoor air pollution to monitor public announcements of air quality, and, depending on the severity of their disease, to avoid vigorous exercise outdoors or stay indoors altogether during pollution episodes. *
Patient education
Education of COPD patients and caregivers is an essential part of good disease management [12, 13] *** . Individualized education should be given on an ongoing basis at patient visits.
Topics for education include:
• Reducing exposure to risk factors, including tobacco smoke • Diet--advice on weight gain where the BMI is below 20 since this increases risk of death, or weight reduction to improve mobility • Importance of regular exercise and maintenance of cardiovascular conditioning • Correct use of medication • Recognizing and treating depression • Management of exacerbations, ideally with a written action plan • End-of-life issues, coping with severe dyspnoea, and palliative care • Recognising and treating co-morbidities.
Rehabilitation
The goal of pulmonary rehabilitation is to reduce symptoms, improve quality of life, and increase participation in everyday activities [14] [15] [16] [17] • Exercise training
The program should contain a minimum of six weeks physical exercise, education, and psychosocial intervention.
Patients at all stages of disease benefit from exercise training programs, with improvements in exercise tolerance and reduction in symptoms of dyspnoea and fatigue. Effective rehabilitation programs can be conducted in inpatient, outpatient, or home settings.
If resources are minimal, benefits can still be gained (Table 2 ) from instructing patients to take regular exercise as appropriate to their environment. It is important to reassure patients that performing exercise to the point of breathlessness is not harmful and will, over time, increase their exercise ability. Lower limb exercises are essential, and patients should be encouraged to walk as far as they can until they are breathless.
Oxygen therapy
Long-term oxygen therapy (LTOT) administered for more than 15 hours per day to COPD patients with chronic respiratory failure improves survival, exercise capacity, and mental state, and has a beneficial impact on pulmonary arterial pressure, polycythemia (defined as a hematocrit of > 55%), exercise capacity, lung mechanics, and mental state [18, 19] *** .
Initiate oxygen therapy for patients with 'Very Severe COPD' (Stage IV) if:
• PaO2 is at or below 7.3 kPa (55 mm Hg) or SaO2 is at or below 88%, with or without hypercapnia; or • PaO2 is between 7.3 kPa (55 mm Hg) and 8.0 kPa (60 mm Hg) or SaO2 is 89%, if there is evidence of pulmonary hypertension, peripheral oedema suggesting congestive heart failure, or polycythemia.
• In primary care, if a pulse oximeter is available, an oxygen saturation (SaO2) of less than 92% should prompt referral for further investigation of the need for oxygen therapy.
The goal of LTOT is to increase the baseline PaO2 at rest to at least 8.0 kPa (60 mm Hg) at sea level, and/or produce an SaO2 of at least 90%, which will preserve vital organ function by ensuring adequate delivery of oxygen.
Oxygen may be administered from an oxygen concentrator, liquid oxygen, or cylinders, depending on cost and the facilities available locally. It is important that patients be carefully monitored, particularly to assess adherence with the recommendation to use oxygen for more than 15 hours each day.
There is no convincing evidence that mechanical ventilatory support, including NIPPV, has a role in the routine management of stable COPD. *
Pharmacological therapy
Although COPD cannot be cured, effective pharmacological therapy can relieve patients' symptoms, increase their ability to accomplish everyday activities, reduce the frequency of exacerbations, and improve their quality of life.
Therapy for COPD does not necessarily produce an improvement in FEV1, although small changes may be seen in lung volume measurements such as inspiratory capacity and residual volume, which are markers of lung hyperinflation. However, such tests cannot be performed easily in primary care.
Therefore, additional subjective measures such as questions about symptoms, quality of life, and exercise tolerance, should be used to gauge the effectiveness of treatment.
Treatments available
Bronchodilators (anticholinergics and beta-2 agonists) are central to symptom management in COPD [20] [21] [22] *** . They are given on a regular basis in 'Moderate' to 'Very Severe' disease, (Stages II-IV) or on an as-needed basis at all stages of the disease in order to relieve breathlessness and improve exercise capacity. For regular treatment, long-acting bronchodilators are more effective [23, 24] *** and more convenient than short-acting bronchodilators, although they are more expensive. 
Therapy by severity
The management of COPD should follow a stepwise approach depending on the severity of the individual patient's disease (Table 3) . Treatment should be symptom-driven.
COPD is typically a slowly progressive disease. Therefore, treatment generally needs to be maintained at the same level over long periods of time and eventually ''stepped up'' as the patient's disease becomes more severe.
Inhaler use
Inhaled medications are preferred in the treatment of COPD because high concentrations of the drug can be delivered directly to the airways, producing potent therapeutic effects with few systemic side effects. However, the wider availability, lower cost, and preference for oral medications in some countries needs to be considered.
Exacerbations
COPD is often associated with exacerbations of symptoms, particularly as the disease progresses.
Most exacerbations are caused by a viral or bacterial infection of the tracheobronchial tree, and some may be caused by an increase in air pollution [26] [27] [28] ** . The cause of about one-third of severe exacerbations cannot, at present, be identified. Figure 1 provides an overview of the management of COPD exacerbations.
Every effort should be made to prevent exacerbations, as they greatly contribute to the erosion in quality of life in COPD patients and can create a serious social and economic burden on the patient, carers, and the health care system.
Signs and symptoms of an exacerbation
Common signs and symptoms of an acute exacerbation of COPD include: • Increased breathlessness, wheeze, and chest tightness • Increased sputum volume • Increased sputum purulence (white becoming yellow or green; green sputum usually points to a bacterial cause) • Non-specific symptoms such as fever, malaise, fatigue, sleepiness, and confusion.
Indications for hospital admission
The risk of dying from an acute exacerbation of COPD is closely related to the development of respiratory acidosis, the presence of serious comorbidities, and the need for ventilatory support.
Patients lacking these features are not at high risk of dying, but those with severe underlying COPD often require hospitalization in any case (see Figure 1 ). Patients with any of the following characteristics should be considered for hospitalisation, although none of the criteria below are absolute indications for hospitalisation:
• Marked increase in intensity of symptoms, such as sudden development of resting dyspnoea 
Pharmacologic therapy Bronchodilators
Increase dose and/or frequency of existing bronchodilator therapy, or add a bronchodilator of another class (e.g., add an anti-cholinergic if a beta 2-agonist is already used, or a beta 2-agonist if an anticholinergic is already used) [29] *** . Higher doses can be administered via a spacer or, for short periods, via nebuliser where available. Both methods can be equally efficacious but when patients are severely dyspnoeic, a nebuliser can be better tolerated.
Oral glucocorticosteroids
These are used to shorten recovery time, increase the time to the next exacerbation, and improve lung function more quickly [30] *** . If the patient is more breathless and wheezy, add oral prednisolone 30-40 mg per day for 7-14 days.
Antibiotics
When symptoms of breathlessness and cough are increased and sputum is purulent and increased in volume, provide antibiotic cover for the major bacterial pathogens involved in exacerbations -Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma catarrhalis -taking into account local patterns of antibiotic sensitivity [31, 32] ** . In primary care it is usually necessary to administer antibiotics prior to the results of sputum culture, if sputum culture has been performed.
Follow-up after exacerbations *
After an exacerbation, the patient should be reviewed periodically until their health status returns to its pre-exacerbation level. The timing and frequency of monitoring should depend on the severity of the exacerbation.
Follow-up after an exacerbation is a good opportunity to review pharmacologic therapy and to consider stepping up treatment or adding rehabilitation, oxygen therapy, or referral to a specialist where appropriate. Smoking cessation should always be re-emphasised. Prolonged symptoms should lead to suspicion of alternative diagnoses such as lung cancer, and require further investigation. Attention should also be paid to strategies for preventing further exacerbations, such as considering the addition of inhaled glucocorticosteroids (see above) to the patient's medication regimen and emphasising the importance of regular influenza vaccination.
Follow-up and on-going care
Patient monitoring * COPD is usually a progressive disease. Lung function can be expected to worsen over time, even with the best available care. Symptoms and lung function should be monitored to follow the development of complications, to guide treatment, and to facilitate discussion of management options. The frequency of monitoring will depend on the health care system and on the individual patient. In general, regular follow-up is needed to:
• Assess the patient's quality of life and whether treatment goals are being met • Assess the patient's ability to cope with the disease and encourage adherence to the treatment plan • Review side effects • Adapt treatment to new advances in therapy.
Review is also recommended after changes in therapy have been made, to assess compliance, understanding, and side effects. This review should take place within a month of the change in treatment.
Adjusting therapy
Treatment for COPD is based on symptoms, and therapy will need to be stepped up as the disease progresses and symptoms worsen or complications develop. However, compliance with the current medication regimen should be assessed before stepping up therapy. Therapy may also be adjusted and alternative medication options tried, when side effects or efficacy are unacceptable.
Referral
Referral to a specialist should be considered if therapy appropriate to the stage of the patient's disease does not control symptoms. Surgical referral for bullectomy or lung transplantation may be considered in carefully selected patients. There is currently insufficient evidence to recommend the widespread use of lung volume reduction surgery (LVRS).
Conclusions and recommendations ***
COPD is a common and important disease. Much can be done to prevent the disease and, once established, to slow or minimise further deterioration. A much more positive attitude needs to be adopted regarding the many benefits that treatments can achieve in terms of symptom relief and improving quality of life. COPD is a systemic disease, and a more holistic approach needs to be focused on associated problems such as muscle deconditioning and psychosocial symptoms associated with COPD. The main areas of management can be summarised as;
• Patient education helps in the understanding of the disease process and adherence to therapy • Stopping smoking is the only intervention that will slow disease progression • Bronchodilators relieve breathlessness and improve exercise ability • Inhaled corticosteroids help to reduce the frequency of acute exacerbations Funding: During the development of these guidelines, the IPCRG received unrestricted educational grants from Altana, AstraZeneca, Boehringer Ingelheim, EAMG, GlaxoSmithKline, Merck Sharp and Dohme, Mitsubishi Pharma, Novartis, UCB Pharma and Zambon. These funds were used for the purpose of funding face-to face-meetings and also to support a secretariat.
Appendix A. Smoking cessation
Clinicians should enquire about smoking habits during general consultations and offer assistance with cessation wherever appropriate. Details about smoking habit should always be recorded in patient records.
Tobacco dependence is a chronic condition that warrants repeated advice and treatment until longterm or permanent abstinence is achieved. Onethird of smokers have made at least three serious attempts to quit, and surveys in some countries suggest that 70% of all smokers want to stop smoking.
Even a brief, 3-minute period of counselling to urge a smoker to quit can be effective *** , and at a minimum this should be done for every smoker at every visit [33] (Figure A1-1) . More intensive group or individual counselling strategies increase the likelihood of sustained quitting *** .
Pharmacotherapy (nicotine replacement and/or buproprion) [34] is recommended when counselling is not sufficient to help patients stop smoking *** . Special consideration should be given before using pharmacotherapy in people smoking fewer than 10 cigarettes per day, pregnant women, adolescents, and those with medical contraindications (unstable coronary artery disease, untreated peptic ulcer, and recent myocardial infarction or stroke for nicotine replacement; a history of seizures for buproprion).
